HBHironori Betsunoh

Hironori Betsunoh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hironori Betsunoh has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic Value of On-Treatment IMDC Risk Score Reassessment in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Immune-Based Combination Therapy

    by Hirotaka Fuchizawa, Toshiki Kijima, Akihiko Nagoshi, Naoki Imasato, Yumeka Arakawa, Gaku Nakamura, Toshitaka Uematsu, Kohei Takei, Hironori Betsunoh, Masahiro Yashi, et al.

    Background: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model is usually assessed before therapy, although five of its six factors may change during treatment. We evaluated whether reassessment at 3 months adds prognostic information during first-line immune-based combination therapy.Methods: This single-center retrospective study included 89 patients with metastatic renal cell carcinoma evaluable at 3 months. Overall survival (OS) and progression-free survival (PFS) were analyzed from the landmark. Cox models evaluated IMDC worsening after adjustment for baseline score and regimen type. Harrell’s concordance index (C-index) was estimated using 2,000 bootstrap resamples.Results: Twenty-five patients (28%) had a higher score at 3 months. The 3-month category was associated with OS and PFS (global log-rank, both P < 0.001). The apparent C-index for OS was 0.597 for the baseline score and 0.688 for the 3-month score; the paired difference was 0.091 (bootstrap 95% confidence interval [CI], −0.022 to 0.198). Adding the 3-month score to the baseline score improved model fit (likelihood-ratio P = 0.003). Worsening was associated with shorter OS (adjusted hazard ratio [HR], 4.34; 95% CI, 1.60–11.79) and PFS (adjusted HR, 2.28; 95% CI, 1.10–4.74). In an exploratory IO+TKI analysis excluding Karnofsky Performance Status decline, the adjusted HR for OS was 8.71 (95% CI, 1.49–50.95). Regimen interactions were not statistically significant.Conclusions: The 3-month IMDC score provided prognostic information beyond baseline. Regimen-specific findings require external validation.

  • Improved preparation of Abraxane ® I.V. Infusion (paclitaxel nanoparticles)

    by Tomoaki Toyama, Hironori Betsunoh, Takeshi Oshizaka, Haruka Mimura, Takuya Sotome, Ryo Fujisawa, Issei Takeuchi, Kenji Mori, Kenji Sugibayashi, Keiko Shinozaki, et al.

    Objective: Abraxane ® intravenous infusion (albumin-bound paclitaxel nanoparticles; Abraxane ® or paclitaxel nanoparticles) is a lyophilized cake formulation containing paclitaxel and human serum albumin in nanoparticulate form. Before use, it must be uniformly dispersed in saline. However, this reconstitution process often leads to foaming, necessitating careful handling and prolonging preparation time. This study aimed to investigate shaking conditions for rapid, uniform paclitaxel nanoparticle dispersion while minimizing foam formation. Additionally, we evaluated whether shaking affects nanoparticle size. Methods: After adding 20 mL of saline to a vial containing 100 mg of lyophilized cake, the vial was placed either vertically or horizontally on a shaker. Two shaking types were examined: linear reciprocal and orbital shaking. We varied shaking intensity and recorded the dispersion time and foam formation. Particle size was analyzed under the following three conditions: (1) control, (2) minimal dispersion time without foaming, and (3) the condition causing the most severe foaming. Results: When the vial was placed horizontally and subjected to orbital shaking at 100 rpm, uniform dispersion was achieved within 6.25 min without foaming. This was approximately one-third the time required under control conditions. Further, when particle size was measured under different shaking intensities in the horizontal setup, no significant change in nanoparticle size was observed regardless of shaking strength or time after preparation. Conclusion: In the reconstitution of Abraxane ® , the optimal shaking condition identified in this study was demonstrated to not only preserve nanoparticle integrity but also reduce the time and effort required for healthcare professionals.


  • Tertiary Lymphoid Structures Correlate With Better Prognosis in Patients With Retroperitoneal Sarcoma: A Retrospective Study

    by Toshiki Kijima, Atsuko Takada‐Owada, Hidetoshi Kokubun, Toshitaka Uematsu, Kohei Takei, Hironori Betsunoh, Masahiro Yashi, Kazuyuki Ishida, Takao Kamai

    Objective: To evaluate the prognostic impact of intratumoral tertiary lymphoid structures (TLSs) in patients with retroperitoneal sarcoma undergoing primary curative surgery, focusing on their relationship with immune microenvironment components and survival outcomes.Methods: We conducted a retrospective analysis of 29 patients who underwent surgical resection for retroperitoneal sarcoma at Dokkyo Medical University Hospital from 2007 to 2021. TLSs and tumor‐infiltrating lymphocytes were assessed in surgical specimens using immunohistochemical staining to identify CD20‐positive B, CD3‐positive T, and CD8‐positive T cells. Disease‐specific survival was analyzed via Kaplan–Meier and Cox proportional hazards models, identifying key prognostic factors.Results: TLSs were identified in 59% of patients, with the highest density in dedifferentiated liposarcoma (DDLPS). TLS‐positive patients showed significantly improved survival compared with TLS‐negative patients, with the greatest survival observed in those with ≥ 10 TLSs per 100 mm2. TLS density was also associated with increased CD8‐positive T‐cell infiltration, indicating a potentially enhanced immune response. In the subset of DDLPS cases, TLS positivity correlated with prolonged survival, underscoring its prognostic value.Conclusions: Intratumoral TLSs are associated with improved survival in retroperitoneal sarcoma, especially DDLPS. These findings highlight the need for further studies on the role of TLS maturity and immune microenvironment dynamics in shaping prognosis and treatment outcomes in retroperitoneal sarcoma.


  • Distribution of the positive UPOINT domain in patients with chronic prostatitis or chronic pelvic pain syndrome: A multicenter observational study

    by Koji Ichihara, Satoshi Takahashi, Yoshiki Hiyama, Naoya Masumori, Hiroshi Nagae, Shin Ito, Koichiro Wada, Hironori Betsunoh, Ryoichi Hamasuna, Yoshikazu Togo, et al.


  • Open Access

    Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma

    by Akinori Masuda, Kyoko Arai, Daisaku Nishihara, Tomoya Mizuno, Hideo Yuki, Tsunehito Kambara, Hironori Betsunoh, Hideyuki Abe, Masahiro Yashi, Yoshitatsu Fukabori, et al.

    To clarify the role of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma (CCRCC), we measured the serum levels of soluble interleukin-2 receptor (sIL-2R), soluble B7-H3 (sB7-H3), and soluble cytotoxic T lymphocyte associated antigen-4 (sCTLA-4) in 70 CCRCC patients and 35 healthy controls. We investigated correlations between the serum levels of these soluble T cell regulatory molecules and the pathological grade, clinical stage, and prognosis of CCRCC. We also assessed the relations among each of these soluble molecules. As a result, the serum level of sIL-2R was significantly higher in CCRCC patients than in healthy controls (P<0.05). In addition, elevation of serum sIL-2R was significantly correlated with the clinical stage (P<0.001), and the survival of patients with high sIL-2R levels was shorter than that of patients with low sIL-2R levels (P<0.05). Furthermore, the serum level of sB7-H3 was also significantly correlated with the clinical stage (P<0.05), while the sIL-2R and sB7-H3 levels showed a positive correlation with each other (R=0.550,P<0.0001). These results indicate that the serum level of sIL-2R reflects tumor progression in CCRCC patients. In addition, the possibility was suggested that the IL-2/IL-2R and B7-H3 pathways may be involved in the progression of CCRCC.


  • 209 FGF7 as a candidate urine biomarker for prostate cancer detection

    by Y. Fukabori, H. Yamazaki, A. Yanagibayashi, M. Yashi, H. Abe, H. Betsunoh, A. Masuda, H. Yuki, K. Arai, T. Kamai